Capricor Therapeutics price target raised to $25 from $8 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Capricor Therapeutics to $25 from $8 and keeps an Overweight rating on the shares. Capricor announced the intent to file the BLA for full approval of deramiocel in DMD following the recent pre-BLA FDA meeting, the analyst tells investors in a research note. The firm is unaware whether the FDA will look to host an Ad Com, but Capricor said they will prepare regardless, and as Capricor’s mechanism of action is unique compared to exon-skippers and gene therapy, the firm doesn’t expect this to be a competitive therapy, but rather potentially used complementarily, Cantor says.